Goldman Sachs
VIR icon

Goldman Sachs’s Vir Biotechnology VIR Stock Holding History

Goldman Sachs’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1M Sell
2,365,219
-885,008
-27% -$8.42M ﹤0.01% 2459
2026
Q1 		$29.1M Buy
3,250,227
+1,681,323
+107% +$13.4M ﹤0.01% 2089
2025
Q4 		$9.46M Buy
1,568,904
+47,102
+3% +$280K ﹤0.01% 3145
2025
Q3 		$8.69M Buy
1,521,802
+231,664
+18% +$1.18M ﹤0.01% 3102
2025
Q2 		$6.5M Buy
1,290,138
+547,464
+74% +$2.94M ﹤0.01% 3163
2025
Q1 		$4.81M Buy
742,674
+225,544
+44% +$2.01M ﹤0.01% 3394
2024
Q4 		$3.8M Sell
517,130
-315,553
-38% -$2.49M ﹤0.01% 3728
2024
Q3 		$6.24M Buy
832,683
+49,884
+6% +$433K ﹤0.01% 3152
2024
Q2 		$6.97M Sell
782,799
-119,543
-13% -$1.15M ﹤0.01% 2855
2024
Q1 		$9.14M Buy
902,342
+324,585
+56% +$3.31M ﹤0.01% 2542
2023
Q4 		$5.81M Buy
577,757
+175,543
+44% +$1.6M ﹤0.01% 3030
2023
Q3 		$3.77M Sell
402,214
-85,688
-18% -$1.22M ﹤0.01% 3241
2023
Q2 		$12M Buy
487,902
+92,095
+23% +$2.31M ﹤0.01% 2276
2023
Q1 		$9.21M Sell
395,807
-221,350
-36% -$5.66M ﹤0.01% 2498
2022
Q4 		$15.6M Sell
617,157
-71,625
-10% -$1.76M ﹤0.01% 2176
2022
Q3 		$13.3M Buy
688,782
+219,702
+47% +$5.59M ﹤0.01% 2245
2022
Q2 		$11.9M Sell
469,080
-148,670
-24% -$3.47M ﹤0.01% 2337
2022
Q1 		$15.9M Buy
617,750
+60,368
+11% +$1.79M ﹤0.01% 2252
2021
Q4 		$23.3M Sell
557,382
-58,713
-10% -$2.3M ﹤0.01% 1978
2021
Q3 		$26.8M Buy
616,095
+96,649
+19% +$4.18M 0.01% 1783
2021
Q2 		$24.6M Sell
519,446
-479,696
-48% -$21.8M 0.01% 1863
2021
Q1 		$51.2M Buy
999,142
+446,909
+81% +$24.1M 0.01% 1155
2020
Q4 		$14.8M Buy
552,233
+146,862
+36% +$4.77M ﹤0.01% 2121
2020
Q3 		$13.9M Buy
405,371
+324,934
+404% +$14M ﹤0.01% 2036
2020
Q2 		$3.29M Buy
80,437
+26,672
+50% +$895K ﹤0.01% 3099
2020
Q1 		$1.84M Buy
53,765
+40,232
+297% +$1.08M ﹤0.01% 3364
2019
Q4 		$170K Buy
+13,533
New +$181K ﹤0.01% 4934

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs's VIR Position: Q2 2026 in Review

Goldman Sachs reduced its Vir Biotechnology (VIR) stake by 27% in Q2 2026, selling an estimated $8.42M and leaving 2,365,219 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2459.

Goldman Sachs first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $51.2M in Q1 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Goldman Sachs held 2,365,219 shares of Vir Biotechnology worth $24.1M as of Q2 2026.
  • Goldman Sachs sold 885,008 Vir Biotechnology shares in Q2 2026, an estimated $8.42M.
  • Vir Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2459 holding.
  • Goldman Sachs first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Goldman Sachs's Vir Biotechnology position peaked at $51.2M in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.